Literature DB >> 17017548

The clinical approach to gait disturbances in Parkinson's disease; maintaining independent mobility.

N Giladi1, Y Balash.   

Abstract

Gait is affected in all stages of Parkinson's disease (PD) and is one of the hallmarks for disease progression. The fear of getting into the wheel chair is one of the first thoughts many patients ask about when the diagnosis of PD is given. At the early stages of the disease gait disturbances are present and can be measured but in most patients it does not cause significant functional disturbances. In contrast, as the disease progress, gait disturbances and postural control abnormalities are becoming major causes for lost of mobility and falls. These unfortunate consequences should be forecasted at the early stages of the disease and a preventive approach should be taken. Treatment of gait disturbances at the early stages of the disease is mainly to encourage patients to exercise and walk daily and by drugs in those with disabling symptoms. At the advanced stages, treatment should be aggressive in order to keep the patient walking safely. Drugs, physiotherapy and functional neurosurgery should be used wisely for best outcomes and least side effects. When time comes and the risk of falls is very significant, walking aids should be suggested and if no other option is left, wheel chair is a very reasonable option to maintain mobility out of home, preserving quality of life and avoiding falls with all it severe consequences.

Entities:  

Mesh:

Year:  2006        PMID: 17017548     DOI: 10.1007/978-3-211-45295-0_49

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  4 in total

1.  Freezing of gait in older adults with high level gait disorders: association with impaired executive function.

Authors:  N Giladi; V Huber-Mahlin; T Herman; J M Hausdorff
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

2.  Neuroprotective Properties of the Standardized Extract from Camellia sinensis (Green Tea) and Its Main Bioactive Components, Epicatechin and Epigallocatechin Gallate, in the 6-OHDA Model of Parkinson's Disease.

Authors:  Natália Bitu Pinto; Bruno da Silva Alexandre; Kelly Rose Tavares Neves; Aline Holanda Silva; Luzia Kalyne A M Leal; Glauce S B Viana
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-18       Impact factor: 2.629

3.  The Parkinson Care Advocate: Integrating Care Delivery.

Authors:  Leonard L Sokol; Debbie Shapiro; Michael J Young; Adina H Wise; Uri P Hadelsberg; Yakir Kaufman; Alberto J Espay; Aristide Merola
Journal:  Front Neurol       Date:  2017-07-27       Impact factor: 4.003

4.  Design of a Machine Learning-Assisted Wearable Accelerometer-Based Automated System for Studying the Effect of Dopaminergic Medicine on Gait Characteristics of Parkinson's Patients.

Authors:  Satyabrata Aich; Pyari Mohan Pradhan; Sabyasachi Chakraborty; Hee-Cheol Kim; Hee-Tae Kim; Hae-Gu Lee; Il Hwan Kim; Moon-Il Joo; Sim Jong Seong; Jinse Park
Journal:  J Healthc Eng       Date:  2020-02-18       Impact factor: 2.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.